 "Sun Pharma ends patent dispute with Actavis")
Under the settlement, Ranbaxy, its partners and Actavis have entered into a non-exclusive agreement which will allow Actavis to sell the generic version of Absorica in December 2020 which is nine months before the expiry of patent.
Ranbaxy and its partners Cipher Pharmaceuticals and Galephar Pharmaceutical Research had filed a suit against Actavis in 2013 for seeking US Food and Drug Administration’s approval to launch a generic version of the drug before expiry of the patent.
The patent to Absorica was held by Galpher but subsequently in 2012 Ranbaxy acquired the exclusive licence to distribute the products in the US.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%